Form 4: IGM Biosciences CEO Sells Shares to Cover Tax Obligations

IGM Biosciences, Inc. CEO Mary Beth Harler sold 1,522 shares of common stock to satisfy tax withholding requirements related to the vesting of restricted stock units.

Summary

• Mary Beth Harler, Chief Executive Officer and Director of IGM Biosciences, Inc. (IGMS), reported a transaction on June 16, 2025.
• The transaction involved the sale of 1,522 shares of IGM Biosciences common stock.
• The shares were sold at a weighted average price of $1.1992 per share.
• The sale was executed in multiple trades with prices ranging from $1.17 to $1.22 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mary Beth Harler directly beneficially owns 338,181 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax obligations associated with equity compensation, rather than a discretionary sale indicating a change in confidence.

Negatives

• The transaction resulted in a slight reduction in the direct beneficial ownership of common stock by the Chief Executive Officer.

Future Outlook

NA

Industry Context

This is a routine insider transaction (Form 4) related to equity compensation and tax obligations, which is common across all industries, including biotechnology, when restricted stock units vest.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as a non-event given the tax-related nature of the sale.

Key Dates

Keywords

IGM Biosciences, IGMS, SEC Form 4, Insider Trading, Stock Sale, CEO, Tax Withholding, Restricted Stock Units, Equity Compensation